Virtual & Traditional Trial Sites: How can they work together?
August 2, 2022

In order to understand the nuances of virtual (i.e. remote-based) and traditional (i.e. brick-and-mortar) trial sites and how they fit together, we need to first understand decentralized clinical trials (DCTs). The exact definition of decentralized clinical trials varies but essentially boils down to this: DCTs move research into patients’ homes and real-world medical settings through the use of technology and local healthcare providers. 

What are decentralized clinical trials?

Often, the label “DCT” is misnomered as digital clinical trials, but it is important to note that decentralized does not necessarily mean digital. DCTs often include protocols for traditional in-person activities such as getting an x-ray at an imaging center. However, digitization remains a key component of decentralized clinical trials through the use of electronic patient reported outcomes (ePROs), electronic clinical outcomes assessments (eCOA), electronic consent (eConsent) telemedicine, wearables, . In fact, decentralization offers the perfect opportunity for traditional and virtual clinical trial sites to work together in a hybrid model study.

What are “traditional” clinical trial sites?

Common examples of traditional clinical trial sites are academic medical institutions or privately owned research centers with the capacity to have the entire study staff on-site. Structurally, the team consists primarily of a principal investigator (PI), responsible for implementing and overseeing the clinical protocol, and clinical research coordinators (CRCs), responsible for managing the day-to-day activities of the study. But, the key point here is that all trial staff are physically present at the site. 

Challenges with Traditional Sites: 

Often, one of the challenges faced by traditional trial sites is geographical limitations. It is common knowledge within the industry that patients are generally not willing to travel far outside of their region to participate in a trial, especially if it requires going to the physical site multiple times throughout the course of the study. This presents a barrier for patient access and engagement and limits the study team’s ability to enroll and retain sufficient participants.

What are “virtual” clinical trial sites?

Virtual trial sites engage local, mobile, and telehealth providers to conduct clinical trial activities. They are managed by a remote-based PI who may oversee sub-investigators, mobile nurses, mobile phlebotomists, remote-based CRCs, and other study staff located across dispersed areas. Trial staff record study data and communicate using technology.

Virtual sites look different for different trials. For one study, a virtual site may constitute five community clinics in Houston overseen by one remote-based PI with remote-based CRCs, located across the United States, meeting with patients via telehealth to review and sign eConsent documents. For another study, a virtual site may be the entire state of Texas. The PI, located in Ontario, manages a team of mobile phlebotomists based in Houston, San Antonio, and Austin with  CRCs assisting remotely from Orlando.

The key difference from traditional sites is that virtual sites have no central location for trial staff. This decentralized structure allows for different types of sites, remote-based and physical, which opens up more opportunities for patients to enroll and engage with physicians they otherwise would not have access to. Virtual sites are also beneficial for sponsors because increased participant enrollment and diversity are highly desirable to all stakeholders. Virtual sites are used to unlock geographic regions where we otherwise would not likely have been able to recruit and manage participants relying on traditional sites alone.

So, how can we use them simultaneously? – In a hybrid model

What are hybrid sites models? This is where a study implements the use of virtual and traditional clinical trial sites to offer a solution that can fill the gaps that may exist with using one of the other. A hybrid model can allow for various aspects of the same study to take place in different settings which are conducive for necessary in-person study activities (such as sample collections, procedures, or treatment administrations), while giving patients access to a remote model that limits the travel required of them.  

Can “traditional” and “virtual” clinical trial sites work together in the same study? Yes. Most clinical studies require at least some in-person activities, whether at home or in a clinical setting. However, one of the major benefits of virtual trial sites is that they can be added into any study alongside traditional trial sites. Virtual and traditional sites can work together. In fact, they are working together already on a number of trials. 

Let’s take a look at some examples:

A pharmaceutical company is running a phase II clinical trial evaluating a new dermatological drug that is stable at room temperature. They are using two well-established academic medical centers in North Carolina but are having trouble recruiting participants who are a bit out of reach due to the limited geographical area. In order to extend the reach of these institutions, the protocol is revised to allow participants who live anywhere in North Carolina to participate from home through the use of remote-based CRCs, mobile phlebotomists, and home drug delivery.  The two existing PIs, in addition to maintaining oversight of the staff at their physical locations, oversee the remote-based staff and interact with participants remotely through the use of robust technology solutions. 

A diagnostic medical device manufacturer is running a US-based pivotal trial. The study activities do not present significant risks to the participants (i.e. primarily blood collection, medical records review, and long-term follow up with participants over a two year period). The company has contracted with a CRO and has activated 75 traditional sites; however, recruitment is slower than anticipated. Despite having a large number of sites, the CRO recognizes that a number of regions, particularly in rural areas, are not covered and they are having difficulty identifying interested and qualified sites in those regions. The CRO decides to supplement their existing sites by setting up 15  virtual sites in underrepresented areas. Each virtual site is able to complete all study activities through the use of a regional, remote-based PI, CRCs, and mobile phlebotomist - supported by fit-for-purpose technology solutions.

A digital therapeutics company is preparing to run a pivotal trial for a digitally delivered cognitive behavioral therapy. Given the risk profile of the intervention and the digital nature of both the therapeutic and the primary endpoints (i.e. clinical outcome assessments that can be captured electronically), the company decides to run a fully decentralized trial, meaning all interactions between participants and site staff will occur remotely. The company partners with vendor(s) capable of providing both the technology and remote site staff required to run the trial. Ultimately, 20 virtual sites are activated within strategic locations to best reach a diverse set of patients that fit the target patient profile. 

The first scenario showcases how virtual trial sites can augment already existing traditional trial sites' capabilities, while the second scenario showcases how virtual trial sites can work alongside traditional trial sites, and the third scenario demonstrates the ability for virtual sites to be the sole solution in limited circumstances.

Full-service DCT vendors can offer hybrid site models that can be designed to specifically cater to the unique needs of a study. This often can include the use of virtual and brick and mortar sites as part of the overall site mix in a study. These study designs can include a variety of digital and service capabilities such as ePRO/eCOA, eConsent, Telemedicine, eSource, Site Portal, Payments, IRT, Scheduling, Wearables, EMR connection, EDC, and more that can be deployed for both the physical and virtual sites to use. Through the implementation of these capabilities and services, we can recruit and retain a greater number of participants, ensure a more diverse and representative study population, and ultimately help bring safe and effective treatments to patients more quickly.


Want to subscribe to our blog?
  • Invisible 1
  • Invisible 2
  • Invisible 3

NEWS: Curebase closes $40M Series B with strategic investment by Gilead. Read about it in TechCrunch, Fierce Biotech, andEndpoints News.

Virtual & Traditional Trial Sites: How can they work together?

August 2, 2022

Most clinical studies require at least some in-person activities; Full-service DCT vendors can offer hybrid solutions which conjoin the services and capabilities of virtual and traditional sites.

In order to understand the nuances of virtual (i.e. remote-based) and traditional (i.e. brick-and-mortar) trial sites and how they fit together, we need to first understand decentralized clinical trials (DCTs). The exact definition of decentralized clinical trials varies but essentially boils down to this: DCTs move research into patients’ homes and real-world medical settings through the use of technology and local healthcare providers. 

What are decentralized clinical trials?

Often, the label “DCT” is misnomered as digital clinical trials, but it is important to note that decentralized does not necessarily mean digital. DCTs often include protocols for traditional in-person activities such as getting an x-ray at an imaging center. However, digitization remains a key component of decentralized clinical trials through the use of electronic patient reported outcomes (ePROs), electronic clinical outcomes assessments (eCOA), electronic consent (eConsent) telemedicine, wearables, . In fact, decentralization offers the perfect opportunity for traditional and virtual clinical trial sites to work together in a hybrid model study.

What are “traditional” clinical trial sites?

Common examples of traditional clinical trial sites are academic medical institutions or privately owned research centers with the capacity to have the entire study staff on-site. Structurally, the team consists primarily of a principal investigator (PI), responsible for implementing and overseeing the clinical protocol, and clinical research coordinators (CRCs), responsible for managing the day-to-day activities of the study. But, the key point here is that all trial staff are physically present at the site. 

Challenges with Traditional Sites: 

Often, one of the challenges faced by traditional trial sites is geographical limitations. It is common knowledge within the industry that patients are generally not willing to travel far outside of their region to participate in a trial, especially if it requires going to the physical site multiple times throughout the course of the study. This presents a barrier for patient access and engagement and limits the study team’s ability to enroll and retain sufficient participants.

What are “virtual” clinical trial sites?

Virtual trial sites engage local, mobile, and telehealth providers to conduct clinical trial activities. They are managed by a remote-based PI who may oversee sub-investigators, mobile nurses, mobile phlebotomists, remote-based CRCs, and other study staff located across dispersed areas. Trial staff record study data and communicate using technology.

Virtual sites look different for different trials. For one study, a virtual site may constitute five community clinics in Houston overseen by one remote-based PI with remote-based CRCs, located across the United States, meeting with patients via telehealth to review and sign eConsent documents. For another study, a virtual site may be the entire state of Texas. The PI, located in Ontario, manages a team of mobile phlebotomists based in Houston, San Antonio, and Austin with  CRCs assisting remotely from Orlando.

The key difference from traditional sites is that virtual sites have no central location for trial staff. This decentralized structure allows for different types of sites, remote-based and physical, which opens up more opportunities for patients to enroll and engage with physicians they otherwise would not have access to. Virtual sites are also beneficial for sponsors because increased participant enrollment and diversity are highly desirable to all stakeholders. Virtual sites are used to unlock geographic regions where we otherwise would not likely have been able to recruit and manage participants relying on traditional sites alone.

So, how can we use them simultaneously? – In a hybrid model

What are hybrid sites models? This is where a study implements the use of virtual and traditional clinical trial sites to offer a solution that can fill the gaps that may exist with using one of the other. A hybrid model can allow for various aspects of the same study to take place in different settings which are conducive for necessary in-person study activities (such as sample collections, procedures, or treatment administrations), while giving patients access to a remote model that limits the travel required of them.  

Can “traditional” and “virtual” clinical trial sites work together in the same study? Yes. Most clinical studies require at least some in-person activities, whether at home or in a clinical setting. However, one of the major benefits of virtual trial sites is that they can be added into any study alongside traditional trial sites. Virtual and traditional sites can work together. In fact, they are working together already on a number of trials. 

Let’s take a look at some examples:

A pharmaceutical company is running a phase II clinical trial evaluating a new dermatological drug that is stable at room temperature. They are using two well-established academic medical centers in North Carolina but are having trouble recruiting participants who are a bit out of reach due to the limited geographical area. In order to extend the reach of these institutions, the protocol is revised to allow participants who live anywhere in North Carolina to participate from home through the use of remote-based CRCs, mobile phlebotomists, and home drug delivery.  The two existing PIs, in addition to maintaining oversight of the staff at their physical locations, oversee the remote-based staff and interact with participants remotely through the use of robust technology solutions. 

A diagnostic medical device manufacturer is running a US-based pivotal trial. The study activities do not present significant risks to the participants (i.e. primarily blood collection, medical records review, and long-term follow up with participants over a two year period). The company has contracted with a CRO and has activated 75 traditional sites; however, recruitment is slower than anticipated. Despite having a large number of sites, the CRO recognizes that a number of regions, particularly in rural areas, are not covered and they are having difficulty identifying interested and qualified sites in those regions. The CRO decides to supplement their existing sites by setting up 15  virtual sites in underrepresented areas. Each virtual site is able to complete all study activities through the use of a regional, remote-based PI, CRCs, and mobile phlebotomist - supported by fit-for-purpose technology solutions.

A digital therapeutics company is preparing to run a pivotal trial for a digitally delivered cognitive behavioral therapy. Given the risk profile of the intervention and the digital nature of both the therapeutic and the primary endpoints (i.e. clinical outcome assessments that can be captured electronically), the company decides to run a fully decentralized trial, meaning all interactions between participants and site staff will occur remotely. The company partners with vendor(s) capable of providing both the technology and remote site staff required to run the trial. Ultimately, 20 virtual sites are activated within strategic locations to best reach a diverse set of patients that fit the target patient profile. 

The first scenario showcases how virtual trial sites can augment already existing traditional trial sites' capabilities, while the second scenario showcases how virtual trial sites can work alongside traditional trial sites, and the third scenario demonstrates the ability for virtual sites to be the sole solution in limited circumstances.

Full-service DCT vendors can offer hybrid site models that can be designed to specifically cater to the unique needs of a study. This often can include the use of virtual and brick and mortar sites as part of the overall site mix in a study. These study designs can include a variety of digital and service capabilities such as ePRO/eCOA, eConsent, Telemedicine, eSource, Site Portal, Payments, IRT, Scheduling, Wearables, EMR connection, EDC, and more that can be deployed for both the physical and virtual sites to use. Through the implementation of these capabilities and services, we can recruit and retain a greater number of participants, ensure a more diverse and representative study population, and ultimately help bring safe and effective treatments to patients more quickly.


More articles from our blog:
Curebase welcomes
Adam Samson as director of clinical operations
June 18, 2020

At Curebase we are rapidly expanding and preparing for the wave of decentralization in clinical trials that we intend to lead. To that end we have recently hired a Director of Clinical Operations, Adam Samson...

Read more
Supporting Women’s health: Addressing gender disparities in clinical trials 
June 24, 2022

Women still face the negative consequences of being excluded from health research. How can we ensure that women are not only included in clinical trials but start to mitigate the detriments of the past?

How decentralized clinical trial models and technology can address common CNS study challenges
May 25, 2022

As the FDA continues to push patient-centricity, careful considerations when planning, building, and executing a CNS trial are ever-growing.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Subscribe to our blog

Get our most recent blogs, whitepapers, webinars and case studies delivered straight to your inbox.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
335 S Van Ness Ave, San Francisco, CA,
94103-3627, United States